What we do

We are Clinical Bioinformatics at the ETH Zurich core facility NEXUS Personalized Health Technologies. Our unit offers highly customizable bioinformatics and biostatistics services for projects in the field of biomedical research and development. We maintain close collaborations with hospitals in Switzerland, enabling and accelerating the use of top-notch data analysis, software development, and clinical decision support. Fee-for-service or joint collaboration, we aim for tailor-made full services for our clients, translating computational and analytical tools to meet their needs.

Find out more about the Group’s activities

Core facility activities

Here are some of the key services we provide (also see here):

  • Bioinformatics/biostatistical data analysis;
  • Translational research support;
  • Clinical decision support;
  • Software development.

Highlights 2020

The Highlights 2020 of CBU revolve around SVIP, Tumor Profiler and of course COVID-19. Our SPHN Infrastructure Development Project SVIP was released as version 1.0 in late November. This marked a milestone for a project spanning multiple groups in all parts of Switzerland. In addition, the source code of SVIP was published on Github. Together with our colleagues at SIB Clinical Bioinformatics we plan to continue our work to establish a central resource for variant interpretation across disciplines and hospitals in 2021 and onwards.

CBU played an important role in the development and implementation of the Research Data Management System (RDMS) of the Tumor Profiler Consortium. The RDMS manages data and procedures coming from multiple technologies and offers a fast-track diagnostic reporting frontend for clinicians. This work was a joint effort including universities, university hospitals, and pharma - translating top-notch methodologies into a clinical setting in multiple cancer types.

Finally, CBU provided infrastructure support for the ETH serological study CoV-ETH, developing, implementing, and maintaining a system to support the clinical trial with respect to visit booking, study questionnaires, and sample tracking in the labs. The CoV-ETH study managed to recruit shy of 3000 participants and will continue until summer 2021. The interplay between the ETH clinical trials platform dTIP, the research labs, and the management of the study participants was an exciting experience and we are looking forward to future trials.

Main Publications 2020

  • Irmisch A et al.
    The Tumor Profiler Study: Integrated, multi-omic, functional tumor profiling for clinical decision support
    Cancer Cell, 10.1016/j.ccell.2021.01.004
  • Stark S G et al.
    SCIM: Universal Single-​Cell Matching with Unpaired Feature Sets
    Bioinformatics, 10.1093/bioinformatics/btaa843
  • Krentel F et al.
    Personalized in-​silico drug response prediction based on the genetic landscape of muscle-​invasive bladder cancer
    bioRxiv, 10.1101/2020.05.22.101428


University zurich

Daniel Stekhoven
Clinical Bioinformatics Unit
ETH Zurich
Group Webpage

Twitter button

Domain(s) of activity:

  • Core facility and competence centre
  • APIs
  • Biostatistics
  • Data visualisation
  • Drug resistance
  • Oncology
  • Personalised medicine
  • Proteomics
  • Single-cell biology
  • Software engineering
  • Transcriptomics

Domain(s) of application:

  • Basic research
  • Medicine and health